ZC3H10: A Potential Drug Target for Cancer (G84872)

Target Name: ZC3H10

NCBI ID: G84872

ZC3H10

ZC3H10: A Potential Drug Target for Cancer

Zinc finger chromatin-containing genes (ZFCGs) are a class of non-coding RNAs that play crucial roles in regulating gene expression and chromosomal stability. ZC3H10 is a Zinc finger gene that is located on chromosome 6 and encodes for a protein known as ZNF21. ZNF21 is a transcription factor that plays a role in the regulation of gene expression and is associated with a variety of diseases, including cancer.

The ZC3H10 gene has four exons, which are encoded by the ZNF21 gene. ZNF21 is a zinc finger gene that contains a conserved zinc finger motif and is characterized by the presence of a hypervariable region (HVR) that is located between the zinc finger domain and the adjacent promoter region. The HVR is responsible for the diversity of ZNF21 transcripts and is involved in the regulation of gene expression.

ZC3H10 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer. ZNF21 is a transcription factor that is known to play a role in the regulation of gene expression and is associated with the development and progression of many diseases, including cancer. By targeting ZC3H10, researchers may be able to gain new insights into the mechanisms of disease progression and the potential for therapeutic intervention.

One of the potential mechanisms by which ZC3H10 may be involved in the development of cancer is its role in the regulation of cell cycle progression. ZNF21 is known to play a role in the regulation of the G1/S transition, which is a critical step in the cell cycle that is involved in the preparation for cell division. Mutations in the ZNF21 gene have been associated with the development of cancer, and researchers are currently studying the mechanisms by which these mutations contribute to disease progression.

Another potential mechanism by which ZC3H10 may be involved in the development of cancer is its role in the regulation of apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. ZNF21 is known to play a role in the regulation of apoptosis, and mutations in the ZNF21 gene have been associated with the development of cancer. Researchers are currently studying the mechanisms by which these mutations contribute to disease progression.

In addition to its potential role in the regulation of cell cycle progression and apoptosis, ZC3H10 may also be involved in the regulation of inflammation. ZNF21 is known to play a role in the regulation of inflammation, and mutations in the ZNF21 gene have been associated with the development of autoimmune diseases. Researchers are currently studying the mechanisms by which these mutations contribute to disease progression.

Overall, ZC3H10 is a Zinc finger gene that is known to play a critical role in the regulation of gene expression and is associated with a variety of diseases, including cancer. By targeting ZC3H10, researchers may be able to gain new insights into the mechanisms of disease progression and the potential for therapeutic intervention.

Protein Name: Zinc Finger CCCH-type Containing 10

Functions: Specific regulator of miRNA biogenesis. Binds, via the C3H1-type zinc finger domains, to the binding motif 5'-GCAGCGC-3' on microRNA pri-MIR143 and negatively regulates the processing to mature microRNA

The "ZC3H10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZC3H10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets